MNSO (09896) Mainland China 26Q3 total GMV increased 25%-30% year over year; proprietary IP YOYO achieved GMV of over RMB 1 billion in the first nine months.
MINISO (09896) announced that for the three months ended September 30, 2026 (26Q3), total GMV in Mainland China increased 25%-30% year over year, further accelerating compared with the first half of 2026, primarily driven by high-single-digit same-store sales growth.
MNSO (09896) announced that the total GMV of MNSO Mainland China for the three months ended September 30, 2026 (26Q3) increased by 25%-30% year over year, further accelerating compared with the first half of 2026, mainly driven by high-single-digit same-store sales growth.
MNSO Mainland China maintained strong momentum during the National Day holiday from October 1 to 7, 2026, with total GMV increasing by 20%-25% year over year, mainly driven by low-single-digit same-store sales growth.
MNSO's flagship proprietary IP
YOYO achieved GMV of over RMB 1 billion in the first nine months of 2026, officially joining the global IP "billion-yuan club." Since the first product launch in June 2025, YOYO has expanded to 53 countries and regions worldwide, becoming one of the fastest Chinese original IPs to achieve scaled global expansion. Mr. Ye Guofu, founder, chairman and chief executive officer of MNSO, said that YOYO has validated MNSO's strategic capability as a "leading global IP operation platform," and MNSO will empower more Chinese original IPs to achieve scaled expansion and accelerated development in the global market.
The performance of MNSO's overseas markets was broadly in line with the company's guidance. In 26Q3, MNSO's U.S. market achieved GMV growth of approximately 20% year over year. Notably, driven by the arrival of new products, its GMV growth in September 2026 rebounded to over 30% year over year, and it achieved positive same-store sales growth.
Related Articles

US Stock Market Move | U.S. clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) debuted on the U.S. stock market, with its share price falling more than 10% after the opening bell.

US Stock Market Move | Trex Bio (TRXB.US) debuts on the U.S. stock market, falling more than 1.3% after the open.

US Stock Market Move | Included in the Nasdaq 100 Index, Moderna (MRNA.US) rises 7%.
US Stock Market Move | U.S. clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) debuted on the U.S. stock market, with its share price falling more than 10% after the opening bell.

US Stock Market Move | Trex Bio (TRXB.US) debuts on the U.S. stock market, falling more than 1.3% after the open.

US Stock Market Move | Included in the Nasdaq 100 Index, Moderna (MRNA.US) rises 7%.






